Provectus today highlighted the clinical outcome of a Stage IV M1d patient in the Company's Phase 1b/2 study of small molecule autolytic cancer immunotherapy PV-10, an injectable formulation of Provectus proprietary rose bengal disodium, in combination with KEYTRUDA for the treatment of advanced cutaneous melanoma in patients refractory to immune checkpoint blockade.
Provectus today highlighted the clinical outcome of a Stage IV M1c patient in the Company's Phase 1b/2 study of small molecule autolytic cancer immunotherapy PV-10, an injectable formulation of Provectus proprietary rose bengal disodium, in combination with KEYTRUDA for the treatment of advanced cutaneous melanoma in patients naïve to immune checkpoint blockade.
The American Herbal Products Association, is excited to present the virtual Sports Nutrition Congress on Oct. 21 to deliver critical information that will help companies capitalize on opportunities, address challenges and help ensure the long-term success of the perpetually growing sport and fitness food and supplement industry.
Provectus today announced that preliminary response, safety, and immune correlative data from the Company's Phase 1b/2 study of small molecule autolytic cancer immunotherapy PV-10, an injectable formulation of Provectus proprietary rose bengal disodium, in combination with KEYTRUDA for the treatment of advanced cutaneous melanoma in patients refractory to immune checkpoint blockade will be pre...
Provectus today announced that 2-year landmark survival, response, and safety data from the Companys Phase 1b/2 study of small molecule autolytic cancer immunotherapy PV-10, an injectable formulation of Provectus proprietary rose bengal disodium, in combination with KEYTRUDA for the treatment of advanced cutaneous melanoma in patients naïve to immune checkpoint blockade will be presented at t...
Momenta Pharmaceuticals, Inc., a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the all-cash tender offer by Vigor Sub, Inc., a wholly owned subsidiary of Johnson & J...
News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.
PDF’s require Adobe® Reader® and will open in a new window.
